Announced details
Acute spinal cord injury and severe cervical spinal cord injury
The organizer of the academic conference at which the Company's clinical trial data will be presented. Capital and personnel relationships: not disclosed.
An academic organization that hosts one of Europe's leading international academic conferences in the field of spinal and spinal cord disorders, attended by specialists, researchers and surgeons from around the world. Other attributes: not disclosed.
London, United Kingdom (venue for the 41st CSRS-Europe Annual Meeting)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Lee et al., Spinal Cord. 52:110-116, 2014
Singh et al., Clin Epidemiol. 6:309-331, 2014
GBD Spinal Cord Injuries Collaborators, Lancet Neurol. 22:1026–1047, 2023
| Item | Details |
|---|---|
| Names of Products / Services Covered | oremepermin alfa (development code: KP-100IT), Recombinant human HGF protein |
| Counterparty | Cervical Spine Research Society-Europe (CSRS-Europe) |
| Counterparty overview | An academic organization that hosts one of Europe's leading international academic conferences in the field of spinal and spinal cord disorders, attended by specialists, researchers and surgeons from around the world. Other attributes: not disclosed. |
| Relationship with the Company | The organizer of the academic conference at which the Company's clinical trial data will be presented. Capital and personnel relationships: not disclosed. |
| Applicable area | Acute spinal cord injury and severe cervical spinal cord injury |
| Location | London, United Kingdom (venue for the 41st CSRS-Europe Annual Meeting) |
| Source | Lee et al., Spinal Cord. 52:110-116, 2014, Singh et al., Clin Epidemiol. 6:309-331, 2014, GBD Spinal Cord Injuries Collaborators, Lancet Neurol. 22:1026–1047, 2023 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To raise awareness of oremepermin alfa in Europe through its presentation at CSRS-Europe, consider development opportunities in Europe in addition to Japan and the United States, and advance global development.